Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

Date

09 Oct 2016

Session

Developmental therapeutics

Presenters

Devalingam Mahalingam

Citation

Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368

Authors

D. Mahalingam1, M.R. Patel2, J.C. Sachdev3, L.L. Hart4, N. Halama5, R.K. Ramanathan6, J. Sarantopoulos7, X. Liu8, S. Yazji8, D. Jäger5, M. Yoon8, G.Ç. Manzur8, D. Adib8, R. Kerschbaumer9, A. Tsimberidou10

Author affiliations

  • 1 Hematology/oncology, Cancer Therapy Research Center, 78229 - San Antonio/US
  • 2 Sarah Cannon Research Institute, Florida Cancer Specialists, 34232 - Sarasota/US
  • 3 Oncology, HonorHealth Research Institute, 85258 - Scottsdale/US
  • 4 Hematology/oncology, Florida Cancer Specialists, 33905 - Ft. Myers/US
  • 5 Oncology, National Center for Tumor Diseases, 69120 - Heidelberg/DE
  • 6 Hematology/oncology, Mayo Clinic Cancer Center, 85259 - Scottsdale/US
  • 7 Oncology, Institute for Drug Development Cancer Therapy Research Center, 78229 - San Antonio/US
  • 8 Clinical, Baxalta, 02142 - Cambridge/US
  • 9 Clinical, Baxalta Innovations GmbH, 113291 - Vienna/AT
  • 10 Investigational Cancer Therapeutics, MD Anderson Cancer Center, 77030 - Houston/US
More

Resources

Abstract 1671

Background

MIF is a pleiotropic cytokine involved in tumor cell proliferation, angiogenesis, and inflammation. oxMIF is the pathogenic isoform found in tumor and its stroma. Imalumab is a novel recombinant, fully human, monoclonal antibody that targets oxMIF, with antitumor activity.

Methods

Dose escalation study (3 + 3 design). Primary endpoint was maximum tolerated dose (MTD). Secondary endpoints were antitumor activity, safety, pharmacokinetics (PK), and pharmacodynamics (PD). Patients (pts), previously treated with other agents, received intravenous (IV) imalumab [28-d cycles; 2 dose schedules]: biweekly in all solid tumors (Q2W); weekly in metastatic colorectal cancer (mCRC), metastatic ovarian cancer (OvCa), and metastatic non-small cell lung cancer (NSCLC) (QW).

Results

50 pts dosed on the trial: 19 (Q2W) in 6 cohorts (1, 3, 10, 25, 37.5, and 50 mg/kg), and 31 (QW) in 2 cohorts (10 and 25 mg/kg) including expansion (10 mg/kg) into mCRC, OvCa, and NSCLC. Dose escalation was stopped at 50 mg/kg (Q2W) and 25 mg/kg (QW). MTD was not reached. One mCRC pt reported dose-limiting toxicities: hypersensitivity pneumonitis (Q2W; 50 mg/kg) at grade 3. One NSCLC pt had grade 3 treatment-related AEs (TRAE): constipation, nausea, and vomiting. Grade 2 TRAEs included: fatigue (n = 2), diarrhea (n = 1), peripheral edema (n = 1), infusion reaction (n = 1), and urticaria (n = 1). Stable disease (SD) ≥4 mo was seen in 8 pts, including 1 pt with NSCLC who achieved SD for 12.6 mo and 1 with OvCa ongoing beyond 10 mo. In DS2, pre- and on-therapy tumor biopsies showed tissue penetration of imalumab resulting in target saturation in all biopsy-evaluable patients in all 3 tumor types. Biopsies revealed regulation of PI3K-AKT-mTOR downstream signaling, TNF-α signaling, anti-inflammatory cytokines (IL-1 and IL-10), and apoptosis. Based on clinical PK and PD study, 10 mg/kg weekly was considered a biologically active dose and sufficient to reach ≥95% target binding by the end of first cycle.

Conclusions

Imalumab 10 mg/kg IV weekly was well tolerated and showed single-agent antitumor activity in these pts.

Clinical trial identification

NCT01765790

Legal entity responsible for the study

Baxalta

Funding

Baxalta

Disclosure

D. Mahalingam: Participated in Ad Boards: Baxter, Genspera, Dendreon, Sanofi, Celgene. X. Liu, S. Yazji, M. Yoon, G.Ç. Manzur, D. Adib: Employee of Baxalta. R. Kerschbaumer: Employee of Celgene A. Tsimberidou: Grants/Research Support Recipient: Onyx, EMD Serono, Baxter, Foundation Medicine All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings